Energex Systems Experimental Therapy Shown to Inactivate Ribonucleic Acid Viruses.

Business Editors/Health/Medical Writers

BIOWIRE2K

EMERSON, N.J.--(BUSINESS WIRE)--Sept. 19, 2003

Energex Systems, Inc. announced today that it has completed several studies of its Hemo-Modulator technology. The studies were designed to determine the safety and effect of the therapy produced by the Hemo-Modulator on Ribonucleic Acid (RNA) viruses. RNA viruses include, but are not limited to, HIV/AIDS, Hepatitis C, SARS, and West Nile.

The three separate, University based studies, designed to determine inactivation, utilized the Corona, West Nile and Semonin Immunodeficient (SIV) viruses. SIV is the laboratory model used in HIV research projects. In all three studies the virus was cultured in a buffered growth medium and then exposed to the ultra violet light emitted by the device. There was a significant, direct effect on inactivation of the virus in all the studies. In the SIV study there was more than 99% inactivation of the virus.

A fourth study, designed to determine safety, analyzed the effect the therapy had on the components of the blood, body tissues and organs. An animal model was used for that study. The conclusion of the study was that there was no evidence of any negative effect and there should be no concern with respect to the safety of the therapy.

The process involves exposing a very small amount of infected blood (3-4%) to a very precise amount of ultra-violet light in the C band (UVC), for a very precise amount of time, explained Thomas Petrie, the developer of the technology and Director of Engineering at Energex Systems. "During treatment, any pathogen in the blood that is exposed to the UVC energy is inactivated. After exposure, the blood carrying the inactive pathogen is returned to the patient through the same portal it was drawn from. The result, we believe, is a stimulation of the immune system. If we can safely inactivate a virus and return it to the patient it came from, the theory of a vaccine suggests that this therapy should be effective in managing these deadly diseases, said Petrie. We didn't develop UVC nor were we the first to theorize that it destroys viruses. What we did, was develop a process to safely expose infected blood to UVC and proved a common theory that it destroys pathogens", said Petrie. The process takes 20-30 minutes.

Based on the results of these studies the Company said it will seek approval from the Federal Food and Drug Administration (FDA) to begin human clinical trials on patients suffering from Hepatitis C.

"We are very excited with the results of these studies and the potential that the technology has to manage these deadly diseases, to reduce the cost of care, and to provide a better quality of life for the millions that suffer from them", said, Thomas J. Fagan, President of the Company. "We are committed to expending whatever resources are necessary to see that this technology continues through the research and approval processes, and that it is accepted by the medical community as the treatment of choice for these diseases," said Mr. Fagan. "Our Hepatitis C study will be the first step in doing that."

Energex Systems is dedicated to developing medical technologies and therapies with an emphasis on the treatment of conditions unmet by present day therapies and reducing the cost of care.